A research group led by Professor MORI Yasuko (of the Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine) has revealed that the HHV-6B glycoprotein complex gH/gL/gQ1/gQ2 is an effective vaccine candidate for human herpesvirus 6B (HHV-6B). There are still no methods to treat nor prevent HHV-6B infection, and this study represents the first attempt in the world at developing a vaccine.
Image/Professor Mori Yasuko/Kobe University
The results were published online in the American scientific journal PLOS Pathogens on July 23.
Main Points
- Human herpesvirus 6B (HHV-6B) is a pathogen that infects the vast majority of people when they are infants. It not only causes exanthem subitum, with symptoms of a fever followed by a skin rash (roseola) but can also trigger severe complications with lasting after-effects such as febrile convulsions, encephalitis (brain inflammation) and encephalopathy.
- Methods to effectively prevent or treat HHV-6B infection have yet to be established. The infection rate is extremely high and great risks are posed by HHV-6B. It is hoped that the realization of a vaccine would enable infants to be inoculated against HHV-6B, resulting in widespread prevention of this virus.
- This research group previously discovered a HHV-6B glycoprotein complex that is an essential factor in HHV-6B infection. In this study, they utilized this complex as a vaccine antigen and analyzed its effectiveness.
- The research group inoculated mice with the purified virus antigen combined with immunostimulants known as adjuvants, demonstrating that this induced effective immunity against HHV-6B. Furthermore, the combination with the adjuvants was also shown to induce cellular immunity.
- These successful results are a big step towards the realization of a safe and effective vaccine for HHV-6B. It is hoped that this research can proceed to clinical trials.
Research Background
Human herpesvirus 6B (HHV-6B) is passed on to infants via the saliva of family members etc., causing exanthem subitum which has symptoms of a fever over 38°C followed by a rash all over the body (roseola). The overwhelming majority of people are infected with HHV-6B. The infection period is between 6 months and 2 years of age; this coincides with the diminishment of antibodies received from the mother.
In most cases, infants recover without experiencing any serious symptoms, however severe complications can occur. For example, it has been reported that in Japan, around 150 infants a year suffer encephalitis or encephalopathy, resulting in lasting aftereffects in around half of this number. Therefore, it is essential to develop a vaccine to protect infants from HHV-6B infection, as there is currently no established treatment nor preventative measures against the virus.
Previously, Professor Mori’s research group discovered the glycoprotein complex gH/gL/gQ1/gQ2, which is expressed on the HHV-6B virus’s surface. They also revealed that the interaction between this complex and CD314 (OX40), which is expressed on stimulated T-cells, is the key to infection (Figure 1). An antibody that targets the gH/gL/gQ1/gQ2 complex would be able to prevent HHV-6B infection. Therefore, the group is also conducting research into generating antibodies that can be used on humans from mice antibodies.
From this accumulated knowledge and experience came the following idea: an efficient immune response against HHV-6B infection could be achieved if inoculation with the gH/gl/gQ1/gQ2 complex induced immunity against the complex.
Research Findings
The researchers developed a vaccine based on the HHV-6B gH/gL/gQ1/gQ2 complex. (A Patent Application for the vaccine has been filed by the BIKEN Foundation and Kobe University (Patent Application No. 2017-509816)). They generated the gH/gL/gQ1/gQ2 complex via genetic modification techniques. This complex was utilized as the vaccine antigen and mice were inoculated with this in combination with an adjuvant, and immunity induction was analyzed .
The HHV-6B gH/gL/gQ1/gQ2 complex is a complicated molecule constructed in a cell with four types of protein. A method was developed to grow this complex in a cultivated cell in which all the proteins are expressed at the same time. It was confirmed that the HHV-6B gH/gL/gQ1/gQ2 complexes generated using this method still retained their function of binding to their target receptor molecule, CD134 (OX40).
The complex was combined with the adjuvant aluminum hydroxide (abbreviated to Alum), which is widely used in current vaccines, and administered to mice in several doses. The immune response was analyzed; the results confirmed there were vaccine induced antibodies against the gH/gL/gQ1/gQ2 complex in the serum of the mice, and their serum had actually prevented HHV-6B from infecting the cells. Furthermore, it was shown that the glycoprotein complex itself had activated dendritic cells, inducing innate immunity.
Furthermore, a vaccine with a combination of oligonucleotide D35 (which can induce cellular immunity) and its transporter, the DOTAP lipid, as adjuvants in addition to Alum was developed. This vaccine was demonstrated to induce an even stronger antibody response. Spleen cells were extracted from mice after the immunity experiments and the immune cell responses to the gH/gL/gQ1/gQ2 complex were investigated. The results showed a stronger response to the antigen in the group inoculated with the Alum/D35/DOTAP combination and confirmed that cellular immunity was induced. Additional analysis results revealed that CD4 T-cells were the main responders to the antigen.
The researchers also investigated whether or not the induction of serum antibodies via inoculation with the gH/gL/gQ1/gQ2 complex actually prevented HHV-6B infection in animals (Figure 3). This experiment utilized immune cell-humanized mice (*5) to develop an animal model of HHV-6B infection. As a negative control, humanized mice were administered with serum from mice that had been given a vaccine containing only the adjuvant. The humanized mice were then injected with HHV-6B. The virus proliferated internally and many virus antigens were detected in the spleens of the negative control group.
On the other hand, the virus did not proliferate in humanized mice that received prior administration of serum from mice who were inoculated with the vaccine containing the gH/gL/gQ1/gQ2 complex. Also, there were hardly any virus antigens in the spleens of these humanized mice. This demonstrates that the induced immunity from the vaccine is efficient against HHV-6B infection in mice.
Further Developments
Effective treatment and preventative methods for HHV-6B infection have yet to be established despite the latent risks that it poses to the health of all infants. The results of this research represent a huge step towards the efficient prevention of HHV-6B infection with a vaccine. It was demonstrated that this vaccine, which used the gH/gL/gQ1/gQ2 complex as an antigen, efficiently induced an immune system response. Also, the vaccine is promising from a safety aspect as it is a subunit vaccine (*6) that does not contain other virus-derived molecules, aside from the complex. Currently, many infants are given a combined inoculation against four diseases called the DPT-IPV vaccine (D: Diphtheria, P: pertussis, T: tetanus and IPV: inactivated polio virus) at 3 months of age. It is hoped that HHV-6B inoculation could be added to this vaccine to prevent infants from contracting it.
After infection, HHV-6B remains latent inside its host for their entire life. It can be reactivated by conditions such as drug-induced hypersensitivity syndrome or a decline in immunity, and has been reported to trigger various illnesses. In particular, this as a problem when hematopoietic stem cell transplants are used to treat leukemia, leading to a high frequency of HHV-6B reactivation which can cause life-threatening encephalitis. The vaccine developed by this study, when combined with adjuvants, not only grants humoral immunity (*7) but can also induce cellular immunity. In other words, this vaccine can induce a strong immune response to HHV-6B. It is believed that it could also be used to suppress the HHV-6B infection in those undergoing hematopoietic stem cell transplants.
Next, the researchers will build upon these results, collect data on the effectiveness and safety of the vaccine and then proceed to clinical trials. They aim to bring a pioneering HHV-6B vaccine developed in Japan to the world.
CURED FROM GENITAL HERPES VIRUS AFTER USING DOCTOR HAZIM HERBAL REMEDY
Herbal supplements have existed for thousands of years and can be traced over several different cultures. For now. Herbs are now used to cure diabetics, herpes, chronic pain, asthma,hepatitis b, cancer , ALS , Ovarian Cyst and even GENITAL HERPES. I like herbs so much. Most of the time, the injection and the drug are only a loss of duration. I was cured of GENITAL HERPES last year with the use of herbs, I suffered from GENITAL HERPES for 13 years, but with the help of DR. Hazim Usman Herbal Medicine, I was cured in a few weeks of using the herbs he sent me by DHL Courier Delivery. I don’t know the kind of health problem you are facing right now, but I assured you that you will be cured if you contact Dr. Hazim Usman and explain your problem to him, that the issues will resolve in a few weeks , contact Dr. Hazim Usman via his e-mail address:—–( [email protected] )—–or reach him via
WHATSAP number—( +2349058026857)—
Anybody who makes claims like this is ridiculous. You don’t know where these “herbs’ come from or are made of. They are still working on cures for Genital Herpes. With all the “cures” you claim this herb can do I imagine you have a very large bank account. For lawsuits that this herb didn’t cure anything. My guess is CBD or THC herbs? They can cure “anything”? Cure cancer? You would be sitting on the biggest throne in the world if you could cure cancer. I see your claims on the internet. From supposedly a variety of folks who were “cured”. No way to respond to them. Just greyed out from the same people who promote this nonsense.
Mr Jerry William dont say what you dont know, herbal medicine is real, and it cure cancer, take a trip to Africa, and check out their herbal practices, these herbalists are real and are healer, one thing you should know is that there is no sickness, diseases/infection that has no cure, God almighty made man and give herbs to man to sort out diseases/infection if needs arise, am a Brazilian i have been to Africa and visit some herbalist i have seen difference herbal medicine for different types of diseases/infections, these people cure cancers,stroke,hepatitis,diabetes and hsv permanently and they aren’t doing it for the money but for the love, which God has bestowed onto men.
my father was down with stroke and a friend of mine here in Sao Paulo, he is from Africa, he introduces me to a herbalist from his country who helped cured my father with herbal medicine.
One thing i know is that all these Big pharmaceutical companies will do anything to make sure that herbal medicine is generally rejected, for instance take Dr Sebi for example, what happen to him, how he was jailed and later died, who do you think is behind all that ? and why ? have you asked yourself ? these are some of the reasons why these herbalist choose to lay low, if you happened to get their contact, get your cure and live a healthy life , and i believed is hard time the world has to know the cruelty of these big pharmaceutical companies toward herbal practices all these comments you seeing online, are people who have benefited from herbal medicine and they are trying to let people know that they can get cured from that diseases/infection, that those medical doctors said can’t be cure , in the real sense no diseases/infections can’t be cure, if you can make a medicine to suppress the outbreak from herpes , why can’t you make the cure ? they have it but they don’t want to release it yet, cause of their selfish interest , firstly they will borne out diseases from their lab and later sell you some retroviral medicine and this rakes in millions for them on monthly basis.. and they wouldn’t allowed any herbalist that came out to challenge their practices, by giving cure to the affected people to see the light of the day.